Of the total, $1 billion will be used to expand viral genome sequencing while the remainder will fund genomic epidemiology centers and new bioinformatics infrastructure.
For 2020, the company reported €128.4 million in revenues, including €89.3 million from COVID-19 testing, more than doubling its 2019 revenues of €48.8 million.
Clinical Enterprises received EUAs for two molecular tests, including one that uses self-collected nasal swab samples, while Qorvo's test detects viral antigens.
